State of Wisconsin Investment Board acquired a new position in shares of ChemoCentryx, Inc. (NASDAQ:CCXI) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 19,000 shares of the biopharmaceutical company’s stock, valued at approximately $178,000.

Several other institutional investors also recently modified their holdings of CCXI. Bank of Montreal Can acquired a new position in shares of ChemoCentryx during the 2nd quarter worth approximately $102,000. Trexquant Investment LP raised its position in shares of ChemoCentryx by 81.1% during the 2nd quarter. Trexquant Investment LP now owns 18,600 shares of the biopharmaceutical company’s stock worth $174,000 after purchasing an additional 8,327 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of ChemoCentryx during the 1st quarter worth approximately $189,000. First Quadrant L P CA acquired a new position in shares of ChemoCentryx during the 2nd quarter worth approximately $219,000. Finally, American Century Companies Inc. acquired a new position in shares of ChemoCentryx during the 1st quarter worth approximately $297,000. Hedge funds and other institutional investors own 50.12% of the company’s stock.

Several brokerages recently issued reports on CCXI. BidaskClub downgraded ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 10th. Zacks Investment Research upgraded ChemoCentryx from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Finally, Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a research report on Tuesday, August 8th.

ChemoCentryx, Inc. (NASDAQ:CCXI) opened at 7.21 on Friday. The company’s 50 day moving average price is $7.81 and its 200 day moving average price is $7.74. ChemoCentryx, Inc. has a 12 month low of $4.62 and a 12 month high of $10.80. The firm’s market capitalization is $351.17 million.

ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.02). The company had revenue of $8.94 million for the quarter. Analysts anticipate that ChemoCentryx, Inc. will post ($0.90) EPS for the current year.

In other news, insider Petrus Bekker sold 30,000 shares of the stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $9.98, for a total transaction of $299,400.00. Following the transaction, the insider now owns 65,963 shares in the company, valued at approximately $658,310.74. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 223,649 shares of company stock valued at $2,157,360. Insiders own 26.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “19,000 Shares in ChemoCentryx, Inc. (CCXI) Acquired by State of Wisconsin Investment Board” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/19000-shares-in-chemocentryx-inc-ccxi-acquired-by-state-of-wisconsin-investment-board/1565402.html.

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.